Shots:
- Amgen has reported topline P-III results assessing Tepezza (SC, Q2W × 12) vs PBO dosed via an on-body injector in pts with mod. to sev. active Thyroid Eye Disease (TED)
- The trial met its 1EP, showing a 76.7% vs 19.6% proptosis response rate, with 3.17 vs 0.80 mm mean proptosis reduction (key 2EP) at 24wks.
- Trial showed significant improvements across additional 2EPs incl. overall responder rate, CAS 0/1, diplopia measures, & GO-QoL appearance score at Wk. 24, while GO-QoL visual function showed numerical improvement with Tepezza OBI; full results will be presented at a medical congress
Ref: Amgen | Image: Amgen |Press Release
Related News: The EC Approves Amgen’s Uplizna (Inebilizumab) to Treat Generalized Myasthenia Gravis (gMG)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
